Jennison Associates
ARQT icon

Jennison Associates’s Arcutis Biotherapeutics ARQT Stock Holding History

Jennison Associates’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$111M Sell
4,219,058
-761,712
-15% -$17.7M 0.07% 150
2026
Q1 		$117M Sell
4,980,770
-1,777,236
-26% -$45.4M 0.08% 114
2025
Q4 		$196M Sell
6,758,006
-5,496,113
-45% -$141M 0.12% 71
2025
Q3 		$231M Buy
12,254,119
+1,144,714
+10% +$18.1M 0.13% 66
2025
Q2 		$156M Sell
11,109,405
-251,470
-2% -$3.53M 0.09% 95
2025
Q1 		$178M Sell
11,360,875
-978,917
-8% -$13.8M 0.12% 86
2024
Q4 		$172M Buy
12,339,792
+676,295
+6% +$7.41M 0.1% 93
2024
Q3 		$108M Buy
11,663,497
+91,803
+0.8% +$906K 0.07% 130
2024
Q2 		$108M Sell
11,571,694
-604,621
-5% -$5.47M 0.07% 117
2024
Q1 		$121M Buy
12,176,315
+3,110,233
+34% +$23.2M 0.08% 102
2023
Q4 		$29.3M Buy
9,066,082
+4,633,907
+105% +$12.6M 0.02% 280
2023
Q3 		$23.5M Buy
4,432,175
+138,209
+3% +$1.18M 0.02% 291
2023
Q2 		$40.9M Buy
4,293,966
+2,079,476
+94% +$23.1M 0.03% 216
2023
Q1 		$24.4M Buy
2,214,490
+816,211
+58% +$11.8M 0.02% 300
2022
Q4 		$20.7M Buy
1,398,279
+8,663
+0.6% +$151K 0.02% 317
2022
Q3 		$26.6M Buy
1,389,616
+954,597
+219% +$21.6M 0.03% 276
2022
Q2 		$9.27M Buy
+435,019
New +$8.92M 0.01% 391

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Jennison Associates's ARQT Position: Q2 2026 in Review

Jennison Associates reduced its Arcutis Biotherapeutics (ARQT) stake by 15% in Q2 2026, selling an estimated $17.7M and leaving 4,219,058 shares worth $111M. The position accounts for 0.07% of the portfolio, ranked #150.

Jennison Associates first reported a position in ARQT in Q2 2022 and has held it in 17 quarters since. The position peaked at $231M in Q3 2025. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Jennison Associates held 4,219,058 shares of Arcutis Biotherapeutics worth $111M as of Q2 2026.
  • Jennison Associates sold 761,712 Arcutis Biotherapeutics shares in Q2 2026, an estimated $17.7M.
  • Arcutis Biotherapeutics made up 0.07% of Jennison Associates's portfolio in Q2 2026, its #150 holding.
  • Jennison Associates first reported a position in Arcutis Biotherapeutics in Q2 2022 and has held it in 17 quarters since.
  • Jennison Associates's Arcutis Biotherapeutics position peaked at $231M in Q3 2025.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Jennison Associates's 13F filing for Q2 2026, filed 3 Aug 2026.